From sequence to scale: Gene editing’s new era in biologics manufacturing

from BioSpace · host BioSpace

In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJack Crawford, CEO, DemeetraMagnus Gustafsson, Chief Commercial Officer, NorthX BiologicsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Episode metadata supplied by the publisher feed · Published Jul 10, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

From sequence to scale: Gene editing’s new era in biologics manufacturing

0:00 20:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 20 minutes long.

When was this BioSpace episode published?

This episode was published on July 10, 2026.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!